Now showing items 1-4 of 4

  • Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas 

    Fack, Fred; Espedal, Heidi; Keunen, Olivier; Golebiewska, Anna; Obad, Nina; Harter, Patrick N.; Mittelbronn, Michel; Bähr, Oliver; Weyerbrock, Astrid; Stuhr, Linda Elin Birkhaug; Miletic, Hrvoje; Sakariassen, Per Øystein; Stieber, Daniel; Rygh, Cecilie Brekke; Lund-Johansen, Morten; Zheng, Liang; Gottlieb, Eyal; Niclou, Simone P.; Bjerkvig, Rolf (Springer, 2015-01)
    Anti-angiogenic therapy in glioblastoma (GBM) has unfortunately not led to the anticipated improvement in patient prognosis. We here describe how human GBM adapts to bevacizumab treatment at the metabolic level. By performing ...
    Journal article
  • Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival 

    Poli, Aurélie; Wang, Jian; Domingues, Olivia; Planagumà, Jesús; Yan, Tao; Rygh, Cecilie Brekke; Skaftnesmo, Kai Ove; Thorsen, Frits Alan; McCormack, Emmet; Hentges, François; Pedersen, Paal-Henning; Zimmer, Jacques; Enger, Per Øyvind; Chekenya, Martha (Impact Journals, 2013-09-09)
    Glioblastoma (GBM) is the most malignant brain tumor where patients’ survival is only 14.6 months, despite multimodal therapy with debulking surgery, concurrent chemotherapy and radiotherapy. There is an urgent, unmet ...
    Journal article
  • Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma 

    Wang, Jian; Svendsen, Agnete; Kmiecik, Justyna; Immervoll, Heike; Skaftnesmo, Kai Ove; Planagumà, Jesús; Reed, Rolf K.; Bjerkvig, Rolf; Miletic, Hrvoje; Enger, Per Øyvind; Rygh, Cecilie Brekke; Chekenya, Martha (PLoS Computational Biology, 2011-07-29)
    Aberrant expression of the progenitor marker Neuron-glia 2 (NG2/CSPG4) or melanoma proteoglycan on cancer cells and angiogenic vasculature is associated with an aggressive disease course in several malignancies including ...
    Peer reviewedJournal article